Health Care Services(IN30222.SG)

Last Updated 07:30:00 SGT
longbridge loading
Company Encyclopedia
View More
name
Health Care Services
IN30222.SG
News
View More

Cordlife renews cord blood and human tissue banking licences

Cordlife Group Limited has renewed its cord blood and human tissue banking service licences. The cord blood banking permit is valid for one year from January 14, 2026, to January 13, 2027, while the human tissue banking licence is valid for two years until January 13, 2028. The renewal comes with specific conditions, including a prohibition on collecting cord blood from infant donors and a requirement to appoint a qualified clinical governance officer. Cordlife had previously halted new cord blood unit activities following a notice from the Ministry of Health regarding potential lapses.

Singapore Business Review·
SG
P8A
-5.66%
Singapore Business Review·
SG
P8A
-5.66%

Cordlife shares jump 18% after renewal of restricted licence

Cordlife shares rose over 18% on January 14 after the Health Ministry renewed its restricted licence for another year, allowing the company to continue storing cord blood. The shares increased from 12.7 cents to 15 cents following the announcement. Cordlife is also facing claims totaling at least $5.45 million from parents regarding damaged cord blood units, which could negatively impact its financial position if ordered to pay this financial year.

Straitstimes·
SG
P8A
-5.66%
Straitstimes·
SG
P8A
-5.66%

Cordlife has been approved to renew its license, and its stock price surged over 18% | Lianhe Zaobao

Cordlife Group, a cord blood bank company, has been granted permission to continue its cord blood storage and human tissue storage services license, with the cord blood license valid until January 13 of next year and the human tissue license valid until January 13, 2028. Nevertheless, the company remains under regulatory restrictions and cannot collect new cord blood. Cordlife's stock price surged over 18% due to the news

Zaobao·
SG
P8A
-5.66%
Zaobao·
SG
P8A
-5.66%

Cordlife Seeks Court Conversion of Cord Blood Claims Case, Warns of Potential FY2026 Hit

Cordlife Group has applied to the High Court to convert existing court claims regarding damage to stored cord blood units into an originating claim. The company warns that an adverse court ruling could negatively impact its financial results for FY2026. Shareholders and potential investors are advised to exercise caution when trading its shares. The latest analyst rating for Cordlife Group (SG:P8A) is a Sell, with a price target of S$0.13. The company specializes in umbilical cord blood storage and has a market cap of S$33.19M.

Tip Ranks·
SG
P8A
-5.66%
Tip Ranks·
SG
P8A
-5.66%

HC Surgical Specialists Lifts Half-Year Profit on Investment Gains, Declares Interim Dividend

HC Surgical Specialists Ltd reported a 17.5% increase in profit attributable to shareholders, reaching S$3.97 million for the six months ended 30 November 2025, despite a slight revenue decline of 1.6% to S$9.78 million. The profit growth was primarily due to non-operational gains. The company declared an interim dividend of S$0.009 per share. Analysts rate the stock as a Buy with a target price of S$0.50. HC Surgical Specialists operates in Singapore's medical and surgical services sector, with a market cap of S$55.37 million.

Tip Ranks·
SG
1B1
+2.74%
Tip Ranks·
SG
1B1
+2.74%
© 2026 Longbridge｜Disclaimer